PT  - JOURNAL ARTICLE
AU  - Killeen, Gerry F.
TI  - A simple arithmetic rationale for crushing the epidemic curve of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) instead of flattening it
AID  - 10.1101/2020.05.06.20093112
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.06.20093112
4099  - http://medrxiv.org/content/early/2020/05/10/2020.05.06.20093112.short
4100  - http://medrxiv.org/content/early/2020/05/10/2020.05.06.20093112.full
AB  - Countries with ambitious strategies to crush the curve of their epidemic trajectories, to promptly eliminate SARS-CoV-2 transmission at national level, include China, Korea, Japan, Taiwan, New Zealand and Australia. In stark contrast, many of the European countries hit hardest over the last two months, including Italy, Spain, France, Ireland and the United Kingdom, currently appear content to merely flatten the curve of their epidemic trajectories so that transmission persists at rates their critical care services can cope with. Here is presented a simple set of arithmetic modelling analyses that explain why preferable crush the curve strategies, to eliminate transmission within months, would require only a modest amount of additional containment effort when compared to flatten the curve strategies that allow epidemics to persist at a steady, supposedly manageable level for years, decades or even indefinitely.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding support was received for this articleAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll models and data for this study are provided as a supplementary file.